Biotech entity
CBER is most often covered alongside FDA, which appears in 2 of these 2 stories. The 12-day window averages about 1.2 stories each week. The 7 average consequence score is above the beat benchmark of 6 in the same window.
Last mentioned: Mar 7, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
CBER is most often covered alongside FDA, which appears in 2 of these 2 stories. The 12-day window averages about 1.2 stories each week. The 7 average consequence score is above the beat benchmark of 6 in the same window. Source depth averages 4 original sources per story, versus 3.2 across the same-window beat baseline. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. This profile follows 2 Biotech stories mentioning CBER across the period from February 24, 2026 to March 7, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 132 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CBER. Shared-story counts are live from our verified record — not editorial picks.
Formal Proposal
FDA formally proposes the new customized drug approval system for ultra-rare diseases.
BGTC Pilot Completion
The Bespoke Gene Therapy Consortium completes its first round of pilot manufacturing runs.
Draft Guidance Issued
FDA releases initial thoughts on 'n-of-1' therapy development and manufacturing.
PREVENT Act Passed
Congress directs FDA to establish a framework for platform technology designations.
The head of the FDA’s vaccine division is stepping down for the second time, marking a significant leadership vacuum at a critical juncture for the agency. This departure follows a period of intense scrutiny and reported friction between the regulatory body and the Trump administration over vaccine authorization protocols.
The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.
CBER is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
